This study aimed to detect the role of JAK2 rs V617F mutation in patients with chronic liver disease (cirrhosis and hepatocellular carcinoma) and clarify its value as a new risk factor for the development of portal vein thrombosis compared to other conventional thrombophilic factors. This evidence concerns the gene JAK2 and Portal vein thrombosis.